Lexicon Pharmaceuticals is actively working to create shareholder value by pursuing new indications for the lead drug sotagliflozin. The company reported $0.7 million in Inpefa sales for Q4 2023, ...

Find the latest Hacker Lexicon news from WIRED. See related science and technology articles, photos, slideshows and videos.

Lexicon is getting closer to FDA approval for sotagliflozin, and the ongoing labeling discussions with the agency may prove critical in differentiating the drug from established rivals. Sotagliflozin ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Investors might want to bet on Lexicon Pharmaceuticals (LXRX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...

Shares of small-cap biotech Lexicon Pharmaceuticals (LXRX-3.59%) fell by nearly 15% during the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The ...

Lexicon Pharmaceuticals has appointed Scott Coiante as its new senior vice president and chief financial officer, effective January 2, 2025. Coiante brings over 35 years of experience in finance ...

Lexicon Pharmaceuticals operates as a contender among biotech stocks by utilizing gene science to develop treatments for chronic conditions. The company primarily focuses on its commercial product, ...

Lexicon Pharmaceuticals announced that it received a complete response letter (CRL) from the FDA regarding its New Drug Application for Zynquista™ (sotagliflozin), which was proposed as an adjunct to ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...